Local Paclitaxel Delivery for Treatment of Peripheral Arterial Disease

Hawkins, Beau M.; Hennebry, Thomas A.

doi:10.1161/circinterventions.110.961052

Cited by 6 publications

(5 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First, local delivery of the drug attenuates neointimal hyperplasia by inhibiting proliferation and migration of smooth muscle cells . The lipophilic and hydrophobic properties of paclitaxel promote its absorption by endothelial cells, allowing adequate concentrations of the drug to be delivered rapidly . Finally, paclitaxel persists in the tissue of target lesions for weeks to months, thereby effectively inhibiting restenosis.…”

Section: Discussionmentioning

confidence: 99%

Mid‐term outcomes of orbital atherectomy combined with drug‐coated balloon angioplasty for treatment of femoropopliteal disease

Foley

Cotter

Kokkinidis

et al. 2017

Cathet Cardio Intervent

View full text Add to dashboard Cite

In this single-center analysis of patients undergoing DCB angioplasty for claudication or CLI, OA was most often used for the treatment of severely calcified lesions. These lesions were more likely to be treated with scoring balloons and less likely to require bailout stenting. At 1 year, target lesion revascularization and primary patency was similar in patients treated with and without adjunctive OA, despite the higher lesion complexity among those receiving the combination procedure. © 2017 Wiley Periodicals, Inc.

show abstract

Section: Discussionmentioning

confidence: 99%

Mid‐term outcomes of orbital atherectomy combined with drug‐coated balloon angioplasty for treatment of femoropopliteal disease

Foley

Cotter

Kokkinidis

et al. 2017

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

“…Recent studies have demonstrated efficacy in reducing NIH in animal models with both intraluminal and perivascular delivery of D-series resolvins (Miyahara, Runge et al 2013, Wu, Mottola et al 2017). For local vascular delivery, the small size and lipophilic nature of SPM as a class provide favorable tissue transfer properties similar to those of currently available therapies (Kotani, Awata et al 2006, Tepe, Zeller et al 2008, Hawkins and Hennebry 2011). …”

Section: Translation: Resolution Pharmacology In Vascular Injurymentioning

confidence: 99%

Resolution of vascular injury: Specialized lipid mediators and their evolving therapeutic implications

Mottola

Schaller

et al. 2017

Molecular Aspects of Medicine

View full text Add to dashboard Cite

Acute vascular injury occurs in a number of important clinical contexts, including spontaneous disease-related events (e.g. plaque rupture, thrombosis) and therapeutic interventions such as angioplasty, stenting, or bypass surgery. Endothelial cell (EC) disruption exposes the underlying matrix, leading to a rapid deposition of platelets, coagulation proteins, and leukocytes. A thrombo-inflammatory response ensues characterized by leukocyte recruitment, vascular smooth muscle cell (VSMC) activation, and the elaboration of cytokines, reactive oxygen species and growth factors within the vessel wall. A resolution phase of vascular injury may be described in which leukocyte efflux, clearance of debris, and re-endothelialization occurs. VSMC migration and proliferation leads to the development of a thickened neointima that may lead to lumen compromise. Subsequent remodeling involves matrix protein deposition, and return of EC and VSMC to quiescence. Recent studies suggest that specialized proresolving lipid mediators (SPM) modulate key aspects of this response, and may constitute an endogenous homeostatic pathway in the vasculature. SPM exert direct effects on vascular cells that counteract inflammatory signals, reduce leukocyte adhesion, and inhibit VSMC migration and proliferation. These effects appear to be largely G-protein coupled receptor-dependent. Across a range of animal models of vascular injury, including balloon angioplasty, bypass grafting, and experimental aneurysm formation, SPM accelerate repair and reduce lesion formation. With bioactivity in the pM-nM range, a lack of discernible cytotoxicity, and a spectrum of vasculo-protective properties, SPM represent a novel class of vascular therapeutics. This review summarizes current research in this field, including a consideration of critical next steps and challenges in translation.

show abstract

“…The PICOLLO and PADI trials are ongoing randomized trials comparing the angiographic outcome of paclitaxel-coated balloons with plain balloon angioplasty in treating below-the-knee lesions. 33,34 Most recently, the PACIFIER Study aims to randomize patients with superficial femoral or popliteal artery disease to paclitaxel-coated or uncoated conventional balloon groups. Results to date of drug-eluting balloons are promising, and their role in infrainguinal disease will be recognized as the clinical trial data accumulates.…”

Section: Drug-eluting Balloonsmentioning

confidence: 99%

Endovascular Techniques in Limb Salvage: Cutting, Cryo, Brachy, and Drug-Eluting Balloons

Anaya‐Ayala

2013

Methodist DeBakey Cardiovascular Journal

View full text Add to dashboard Cite

Local Paclitaxel Delivery for Treatment of Peripheral Arterial Disease

Cited by 6 publications

References 50 publications

Mid‐term outcomes of orbital atherectomy combined with drug‐coated balloon angioplasty for treatment of femoropopliteal disease

Mid‐term outcomes of orbital atherectomy combined with drug‐coated balloon angioplasty for treatment of femoropopliteal disease

Resolution of vascular injury: Specialized lipid mediators and their evolving therapeutic implications

Endovascular Techniques in Limb Salvage: Cutting, Cryo, Brachy, and Drug-Eluting Balloons

Contact Info

Product

Resources

About